Apixaban Has Lower Bleeding Risk for Initial Anticoagulation for Venous Thromboembolism
During extended treatment, bleeding risk was similar for apixaban and rivaroxaban.
During extended treatment, bleeding risk was similar for apixaban and rivaroxaban.
Researchers sought to determine risk factors for developing VTE among patients with thrombophilia and cancer who were receiving chemotherapy.
Researchers sought to determine whether direct oral anticoagulant or warfarin would be better for recurrent VTE in patients taking extended anticoagulation treatment.
Researchers sought to determine the healthcare resource utilization, costs, and mortality associated with patients with polycythemia vera who had thromboembolic events.
Investigators aimed to validate the performance of 3 different models for the prediction of thrombosis recurrence among patients with antiphospholipid syndrome.
Findings seen among adults prescribed warfarin, DOACs beyond six months after acute venous thromboembolism.
Researchers sought to determine whether carfilzomib with lenalidomide and dexamethasone would increase risk of VTE in patients with MM compared with bortezomib plus lenalidomide and dexamethasone.
Researchers sought to determine the different characteristics for acute VTE in young adults and older adults.
Researchers sought to determine whether VTE would be associated with higher all-cause mortality in patients with PNH.
Researchers sought to determine whether direct oral anticoagulants would do as well in preventing VTE in patients with cancer as LMW heparin